Michael Chi Sells 14,027 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the transaction, the chief operating officer owned 456,660 shares in the company, valued at $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Trading Up 0.4%

HIMS stock opened at $28.00 on Friday. The company has a market capitalization of $6.53 billion, a PE ratio of -44.45 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The company’s 50 day moving average price is $30.06 and its two-hundred day moving average price is $27.60.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period last year, the company posted $0.17 EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: CFO Oluyemi Okupe sold 12,313 shares worth approximately $355,000, reducing his position by 4.66%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, making it a weaker standalone bearish signal. CFO SEC filing
• Neutral Sentiment: COO Michael Chi sold 14,027 shares for about $398,000, while insider Soleil Boughton sold 6,236 shares for approximately $174,000. Both sales were made through pre-arranged Rule 10b5-1 plans; however, the cluster of insider sales may still reinforce investor caution. Insider SEC filing
• Negative Sentiment: Multiple law firms announced or promoted a securities class action against HIMS involving investors who purchased shares between August 4, 2025, and July 29, 2026. The deadline to seek lead-plaintiff status is November 2, 2026, increasing headline and litigation risk. Securities class action report
• Negative Sentiment: The lawsuits stem from allegations related to the FTC’s complaint, including potential misstatements or omissions concerning Hims & Hers’ privacy, data-sharing, billing and business practices. The allegations remain unproven, but could lead to legal costs, regulatory consequences and reputational damage. HIMS lawsuit allegations

Analyst Ratings Changes

A number of brokerages have commented on HIMS. Citigroup decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Truist Financial increased their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, TD Cowen boosted their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. Bienville Capital Management LLC bought a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $27,242,000. Engineers Gate Manager LP bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $232,000. Integrated Wealth Concepts LLC purchased a new stake in Hims & Hers Health in the second quarter worth $147,000. Baird Financial Group Inc. grew its stake in Hims & Hers Health by 384.6% in the second quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock worth $2,273,000 after purchasing an additional 52,043 shares during the period. Finally, Nykredit A S bought a new position in Hims & Hers Health in the second quarter worth $222,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.